Advertisement
Screener

HERON THERAPEUTICS, INC. /DE/ (HRTX) Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent

2.8 / 5 stars · 68/120 Roast Me

HERON THERAPEUTICS, INC. /DE/ Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent

HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent of -$51.31 million for the 3-month period ending 2018-12-31, per its 10-K filed 2019-02-22.

Discontinued › Income Statement › Net Income

us-gaap:IncomeLossFromContinuingOperations · last filed 2019-02-22

  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2018-12-31 was -$51.31M.
  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2018-09-30 was -$41.78M.
  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2018-06-30 was -$38.85M.
  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2018-03-31 was -$51.99M.
  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2014 was -$76.37M.
  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2013 was -$55.28M.
  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2012 was -$24.43M.
  • HERON THERAPEUTICS, INC. /DE/ income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2011 was -$11.44M.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month
2018-12-31-$51.31M
10-K · filed 2019-02-22
-$93.09M
derived: sum of 2 quarters · filed 2019-02-22
-$131.95M
derived: sum of 3 quarters · filed 2019-02-22
-$183.94M
derived: sum of 4 quarters · filed 2019-02-22
2018-09-30-$41.78M
10-K · filed 2019-02-22
-$80.63M
derived: sum of 2 quarters · filed 2019-02-22
-$132.62M
derived: sum of 3 quarters · filed 2019-02-22
-$194.51M
derived: sum of 4 quarters · filed 2019-02-22
2018-06-30-$38.85M
10-K · filed 2019-02-22
-$90.84M
derived: sum of 2 quarters · filed 2019-02-22
-$152.73M
derived: sum of 3 quarters · filed 2019-02-22
-$194.05M
derived: sum of 4 quarters · filed 2019-02-22
2018-03-31-$51.99M
10-K · filed 2019-02-22
-$113.88M
derived: sum of 2 quarters · filed 2019-02-22
-$155.19M
derived: sum of 3 quarters · filed 2019-02-22
-$197.25M
derived: sum of 4 quarters · filed 2019-02-22
2017-12-31-$61.89M
10-K · filed 2019-02-22
-$103.20M
derived: sum of 2 quarters · filed 2019-02-22
-$145.26M
derived: sum of 3 quarters · filed 2019-02-22
-$194.56M
derived: sum of 4 quarters · filed 2019-02-22
2017-09-30-$41.31M
10-K · filed 2019-02-22
-$83.37M
derived: sum of 2 quarters · filed 2019-02-22
-$132.67M
derived: sum of 3 quarters · filed 2019-02-22
-$179.47M
derived: sum of 4 quarters · filed 2019-02-22
2017-06-30-$42.05M
10-K · filed 2019-02-22
-$91.35M
derived: sum of 2 quarters · filed 2019-02-22
-$138.16M
derived: sum of 3 quarters · filed 2019-02-22
-$185.89M
derived: sum of 4 quarters · filed 2019-02-22
2017-03-31-$49.30M
10-K · filed 2019-02-22
-$96.10M
derived: sum of 2 quarters · filed 2019-02-22
-$143.84M
derived: sum of 3 quarters · filed 2019-02-22
-$186.90M
derived: sum of 4 quarters · filed 2019-02-22
2016-12-31-$46.80M
10-K · filed 2018-02-27
-$94.54M
derived: sum of 2 quarters · filed 2018-02-27
-$137.60M
derived: sum of 3 quarters · filed 2018-02-27
-$170.91M
derived: sum of 4 quarters · filed 2018-02-27
2016-09-30-$47.73M
10-K · filed 2018-02-27
-$90.80M
derived: sum of 2 quarters · filed 2018-02-27
-$124.11M
derived: sum of 3 quarters · filed 2018-02-27
-$155.17M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30-$43.07M
10-K · filed 2018-02-27
-$76.38M
derived: sum of 2 quarters · filed 2018-02-27
-$107.44M
derived: sum of 3 quarters · filed 2018-02-27
-$129.93M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31-$33.31M
10-K · filed 2018-02-27
-$64.37M
derived: sum of 2 quarters · filed 2018-02-27
-$86.86M
derived: sum of 3 quarters · filed 2018-02-27
-$109.88M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31-$31.06M
10-K · filed 2017-02-23
-$53.55M
derived: sum of 2 quarters · filed 2017-02-23
-$76.56M
derived: sum of 3 quarters · filed 2017-02-23
-$96.92M
derived: sum of 4 quarters · filed 2017-02-23
2015-09-30-$22.49M
10-K · filed 2017-02-23
-$45.51M
derived: sum of 2 quarters · filed 2017-02-23
-$65.86M
derived: sum of 3 quarters · filed 2017-02-23
-$85.36M
derived: sum of 4 quarters · filed 2017-02-23
2015-06-30-$23.01M
10-K · filed 2017-02-23
-$43.37M
derived: sum of 2 quarters · filed 2017-02-23
-$62.87M
derived: sum of 3 quarters · filed 2017-02-23
-$81.82M
derived: sum of 4 quarters · filed 2017-02-23
2015-03-31-$20.36M
10-K · filed 2017-02-23
-$39.85M
derived: sum of 2 quarters · filed 2017-02-23
-$58.81M
derived: sum of 3 quarters · filed 2017-02-23
-$77.60M
derived: sum of 4 quarters · filed 2017-02-23
2014-12-31-$19.50M
10-K · filed 2016-02-19
-$38.45M
derived: sum of 2 quarters · filed 2016-02-19
-$57.24M
derived: sum of 3 quarters · filed 2016-02-19
-$76.37M
10-K · filed 2015-03-13
2014-09-30-$18.95M
10-K · filed 2016-02-19
-$37.74M
derived: sum of 2 quarters · filed 2016-02-19
-$55.07M
derived: sum of 3 quarters · filed 2016-02-19
-$68.90M
derived: sum of 4 quarters · filed 2016-02-19
2014-06-30-$18.79M
10-K · filed 2016-02-19
-$36.11M
derived: sum of 2 quarters · filed 2016-02-19
-$49.94M
derived: sum of 3 quarters · filed 2016-02-19
-$62.61M
derived: sum of 4 quarters · filed 2016-02-19
2014-03-31-$17.32M
10-K · filed 2016-02-19
-$31.15M
derived: sum of 2 quarters · filed 2016-02-19
-$43.82M
derived: sum of 3 quarters · filed 2016-02-19
-$59.03M
derived: sum of 4 quarters · filed 2016-02-19
2013-12-31-$13.83M
10-K · filed 2015-03-13
-$26.50M
derived: sum of 2 quarters · filed 2015-03-13
-$41.70M
derived: sum of 3 quarters · filed 2015-03-13
-$55.28M
10-K · filed 2015-03-13
2013-09-30-$12.66M
10-K · filed 2015-03-13
-$12.87M
10-Q · filed 2013-11-12
-$27.87M
derived: sum of 2 quarters · filed 2015-03-13
-$41.24M
10-Q · filed 2013-11-12
-$49.65M
derived: sum of 4 quarters · filed 2015-03-13
2013-06-30-$15.21M
10-K · filed 2015-03-13
-$15.41M
10-Q · filed 2013-08-08
-$28.37M
10-Q · filed 2013-08-08
-$36.99M
derived: sum of 3 quarters · filed 2015-03-13
-$43.24M
derived: sum of 4 quarters · filed 2015-03-13
2013-03-31-$12.95M
10-Q · filed 2013-05-10
-$21.78M
derived: sum of 2 quarters · filed 2014-03-07
-$28.03M
derived: sum of 3 quarters · filed 2014-03-07
-$32.55M
derived: sum of 4 quarters · filed 2014-03-07
2012-12-31-$8.82M
10-K · filed 2014-03-07
-$15.07M
derived: sum of 2 quarters · filed 2014-03-07
-$19.60M
derived: sum of 3 quarters · filed 2014-03-07
-$24.43M
10-K · filed 2015-03-13
2012-09-30-$6.25M
10-K · filed 2014-03-07
-$10.78M
derived: sum of 2 quarters · filed 2014-03-07
-$15.61M
10-Q · filed 2013-11-12
-$27.69M
derived: sum of 4 quarters · filed 2015-03-13
2012-06-30-$4.53M
10-K · filed 2014-03-07
-$9.36M
10-Q · filed 2013-08-08
-$21.44M
derived: sum of 3 quarters · filed 2015-03-13
-$25.59M
derived: sum of 4 quarters · filed 2015-03-13
2012-03-31-$12.75M
10-K · filed 2015-03-13
-$4.83M
10-K · filed 2013-03-01
-$16.92M
derived: sum of 2 quarters · filed 2015-03-13
-$21.07M
derived: sum of 3 quarters · filed 2015-03-13
-$22.87M
derived: sum of 4 quarters · filed 2015-03-13
2011-12-31-$4.17M
10-K · filed 2013-03-01
-$8.32M
derived: sum of 2 quarters · filed 2013-03-01
-$10.12M
derived: sum of 3 quarters · filed 2013-03-01
-$11.44M
10-K · filed 2014-03-07
2011-09-30-$4.15M
10-K · filed 2013-03-01
-$5.95M
derived: sum of 2 quarters · filed 2013-03-01
-$7.27M
10-Q · filed 2012-11-05
-$8.76M
derived: sum of 4 quarters · filed 2013-03-01
2011-06-30-$1.80M
10-K · filed 2013-03-01
-$3.12M
10-Q · filed 2012-08-09
-$4.61M
derived: sum of 3 quarters · filed 2013-03-01
-$6.25M
derived: sum of 4 quarters · filed 2013-03-01
2011-03-31-$1.32M
10-K · filed 2013-03-01
-$2.81M
derived: sum of 2 quarters · filed 2013-03-01
-$4.45M
derived: sum of 3 quarters · filed 2013-03-01
-$8.14M
derived: sum of 4 quarters · filed 2013-03-01
2010-12-31-$1.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01
-$3.13M
derived: sum of 2 quarters · filed 2013-03-01
-$6.82M
derived: sum of 3 quarters · filed 2013-03-01
-$7.20M
10-K · filed 2013-03-01
2010-09-30-$1.64M
10-Q · filed 2011-11-07
-$5.33M
derived: sum of 2 quarters · filed 2011-11-07
-$5.70M
10-Q · filed 2011-11-07
2010-06-30-$3.69M
10-Q · filed 2011-08-08
-$4.07M
10-Q · filed 2011-08-08
2009-12-31-$10.10M
10-K · filed 2012-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Clene Inc. (CLNN)United States$0.054B-1.99
Serina Therapeutics, Inc. (SER)United States$0.054B-2.35
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
Xilio Therapeutics, Inc. (XLO)United States$0.052B
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
TALPHERA, INC. (TLPH)United States$0.060B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
CalciMedica, Inc. (CALC)United States$0.061B-1.42
Lite Strategy, Inc. (LITS)United States$0.049B